UCB
UCB SA is a global biopharmaceutical enterprise specializing in the discovery, clinical development, and commercialization of innovative medicines for severe diseases. The company concentrates its research and commercial operations across two primary therapeutic focus areas: neurology and immunology. Its key commercial product portfolio includes biopharmaceutical therapeutics such as Bimzelx, Cimzia, Evenity, Vimpat, and Keppra, addressing conditions such as severe psoriasis, rheumatoid arthritis, postmenopausal osteoporosis, and epilepsy. Principal revenue drivers consist of global commercial sales of proprietary prescription pharmaceuticals, alongside strategic licensing agreements and research partnerships. UCB serves international end markets encompassing hospital networks, specialty care clinics, wholesale drug distributors, government health authorities, and patients across Europe, the Americas, and Asia-Pacific. The company holds a prominent market position in global immunology and central nervous system therapeutics as a major European biopharmaceutical manufacturer. Headquartered in Brussels, Belgium, UCB's common stock is publicly traded on the Euronext Brussels stock exchange under the ticker symbol UCB.
116 of the funds FundTelligence covers report a position in UCB.
- Legal name
- UCB SA
- Sector
- Health Care
- Country
- Belgium
- Funds holding it
- 116
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding UCB
- DNB Fund Women's Health — DNB · 4.07 % (full portfolio disclosed, August 2026)
- DWS Invest CROCI Euro — DWS · 3.45 % (full portfolio disclosed, June 2026)
- DNB Bioteknologi — DNB · 3.43 % (full portfolio disclosed, September 2026)
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 2.5 % (partially disclosed portfolio, September 2026)
- BNP Health Care Innovators — BNP Paribas · 2.36 % (full portfolio disclosed, June 2026)
- SEB Läkemedelsfond — SEB · 2.14 % (full portfolio disclosed, June 2026)
- Schroder ISF European Sustainable Equity — Schroders · 2.13 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 2.0 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 116 funds holding it.